Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Defensives are in favor
Fri, 11 Jul 01:30 pm

Indian share markets continued to slide further in the post-noon trading session. Barring IT, FMCG and pharma, all the sectoral indices are trading in the red. Power, realty and capital goods stocks are the biggest gainers.

BSE-Sensex is down 152 points and NSE-Nifty is trading 58 points down. BSE Mid Cap is trading 1.8% up and BSE Small Cap index is trading down by 2%. The rupee is trading at 60.16 to the US dollar.

Majority of the food & tobacco stocks are trading in the red with Tata Global Beverages and United Spirits being the major losers, whereas Godfrey Phillips and ITC are among the few stocks trading in the green. As per a leading financial daily, Britannia Industries has sold off its factory land in Chennai for Rs 1.7 bn. The factory land spread across 16 acres in Padi in Chennai was closed for almost a year. Additionally, the company is considering developing a 6 acre plot in Bangalore where its headquarters are located. Reportedly this land parcel can fetch the company around Rs 4.5 bn. Britannia posted an 11.8% YoY growth in topline in FY14. The company saw a significant improvement in profit margins during the year on the back of benign commodity prices as well as cost savings from increased in-house manufacturing.

Indian pharma stocks are trading mixed today. Aurobindo Pharma and Sun Pharma are leading the pack of gainers, whereas Dishman Pharma is trading in the red. As per a leading business daily, Sun Pharma's subsidiary Caraco Pharmaceutical is expected to recall some lots of antidepressant drug Venlafaxine Hydrochloride from the US market. The company has initiated talks for the same and according to FDA notification, it will recall 26,530 units of 30-count bottles and 14,597 units of 90-count bottles voluntarily. This recall is as per regulator's Class II classification in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences. Venlafaxine Hydrochloride is an extended-release tablet used for the treatment of major depressive disorder. The recall, as per the company letter to FDA, is because the product does not meet the drug release dissolution specifications on stability results. This affects the treatment for which the drug is intended for. The recalled is drug was manufactured at Sun Pharma's plant in Halol, Gujarat.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Defensives are in favor". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.